TransMedics Group, Inc. — FY2023 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2023; it is not a standalone fourth-quarter report. TransMedics develops the Organ Care System (OCS), a portable warm-perfusion platform for heart, lung and liver transplantation, and provides U.S. retrieval, organ-management and logistics services through its National OCS Program (NOP). All three OCS products have FDA premarket approval for specified indications. The company added aviation transportation through its August 2023 acquisition of Summit Aviation.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $241.6 million | $93.5 million |
| Product revenue | $176.1 million | $79.2 million |
| Service revenue | $65.6 million | $14.2 million |
| Gross profit / gross margin | $154.1 million / 64% | $65.3 million / 70% |
| Operating loss | $28.7 million | $31.4 million |
| Net loss | $25.0 million | $36.2 million |
| Net cash used in operating activities | $13.0 million | $45.8 million |
Revenue grew 158.5% year over year. U.S. OCS transplant revenue was $221.3 million, up $137.3 million; international OCS transplant revenue was $15.4 million, up $6.0 million. The filing separately reports $4.9 million of Summit legacy service revenue unrelated to OCS transplantation.
Product gross margin was 77% versus 79%; service gross margin was 29% versus 21%. Management attributed the overall margin decline mainly to services becoming a larger share of revenue; product margin also reflected manufacturing-capacity expansion and higher costs for certain parts.
At year-end, cash was $394.8 million, total current assets were $510.7 million and current liabilities were $54.9 million. Operating cash use improved year over year, but remained negative. Investing activities used $194.0 million, including $141.9 million for transplant aircraft, $27.2 million for acquired in-process R&D assets and $14.9 million net for Summit. Financing activities provided $400.4 million.
Debt included $460.0 million principal of 1.50% convertible notes due June 2028 and $60.0 million principal under the CIBC credit agreement. The CIBC loan carried a 7.3% stated rate at year-end; principal repayments begin in July 2026 and continue through its July 2027 maturity. The notes’ initial conversion price was approximately $94 per share. The company spent $52.1 million on capped-call transactions in connection with the notes. It reported compliance with CIBC covenants at December 31, 2023.
Material changes versus the prior year
- U.S. growth was led by higher OCS Liver and Heart disposable-set volumes and broader NOP use; substantially all U.S. customers participated in NOP.
- Service revenue rose substantially with NOP expansion and new transportation and logistics services. The service mix reduced consolidated gross margin.
- Operating expenses increased to $182.8 million from $96.7 million. This included $27.2 million of acquired in-process R&D expense for Bridge to Life heart and lung perfusion technology; SG&A rose to $119.6 million, primarily reflecting growth in personnel, professional fees and NOP support.
- The Summit acquisition added aircraft operations and increased property, plant and equipment. The company acquired 11 transplant-related aircraft in 2023 and two more in January and February 2024 for $26.6 million in total.
- Interest expense increased to $10.8 million, mainly due to the convertible notes. Other income included $12.5 million of interest income on invested cash, compared with $0.9 million in 2022.
Outlook, commentary, risks and unusual items
Management expects long-term revenue growth from expansion of NOP and international sales, particularly if foreign health systems establish reimbursement. It expects operating and capital spending to continue increasing for commercial expansion, aircraft, manufacturing, R&D and regulatory work. Management stated that year-end cash should fund operating expenses, capital requirements and debt service for at least 12 months after the February 27, 2024 filing date, while cautioning that assumptions may prove inaccurate. The filing provides no specific numerical revenue or earnings guidance.
Key risks include continued losses (the company has never generated annual net income), dependence on OCS adoption and reimbursement, reliance on NOP execution, operational and regulatory risks from aircraft services, pilot availability and aviation safety, supplier and sterilization concentration, manufacturing scale-up, competition, and the ability to service debt. International reimbursement remains limited, and management is seeking longer-term coverage in selected markets. A second-quarter 2023 cyber incident involved unauthorized data theft; the company said no sensitive data were involved and the incident’s operational impact was not material. It reported no material legal proceedings. No dividends have been paid or are anticipated in the foreseeable future.
The independent auditor issued an unqualified opinion on the consolidated financial statements and concluded internal control over financial reporting was effective. Summit was excluded from management’s and the auditor’s internal-control assessment because it was acquired during 2023.
Most important facts for investors to verify
- Whether revenue growth and OCS utilization persist, particularly in U.S. liver and heart procedures, and how much growth comes from product sales versus NOP services.
- Whether service margins improve with scale and whether consolidated margins can recover as logistics and aircraft operations expand.
- Cash burn, aircraft and other capital spending, and the company’s liquidity runway relative to its stated 12-month estimate.
- Debt terms and covenant headroom, including CIBC’s revenue and liquidity requirements and potential dilution or cash-settlement effects of convertible-note conversion.
- Progress on international reimbursement, post-approval studies, regulatory approvals and development of next-generation products.
- Execution and safety of owned-aircraft operations, pilot recruitment, and continued availability of critical single-source supplies and sterilization.